Icon times
Cipla Stock Fundamental Analysis - Financial Results & Equity Research | Investyadnya Stock-o-Meter

Cipla

CompanyOver

 / 

Highlights

Performing rate for the company

Highlights

undefined

Price Chart (Only Standalone)

PE Price

Quarterly Results ( Figures in Rs. Crores.)

Profit & Loss ( Figures in Rs. Crores.)

Balance Sheet ( Figures in Rs. Crores.)

Cash Flows ( Figures in Rs. Crores.)

Historical Growths

Compounded Sales Growth
Compounded Profit Growth
Compounded Expense Growth
Stock Price CAGR

Ratios ()

Major Shareholders

Shareholders more than 1%

No Data is available.
No Data is available.
No Data is available.
No Data is available.

Documents

Presentation & Earning Calls

Annual Reports

Credit Rating

No document is available
No document is available
No document is available
No document is available.

Overview

CIPLA

OVERVIEW

Cipla was founded as The Chemical, Industrial, & Pharmaceutical Laboratories by Khwaja Abdul Hamied in 1935. It is a market-leading renowned medicine producer in India. The company has approximately 2,000 pharmaceutical products in more than 60 therapeutic categories. With their motto as caring for life, the drugs are sold domestically, while others reach global markets in more than 170 nations. They brought a revolution when it comes to affordable medicines and pharmaceuticals in India and abroad. Cipla leads the domestic retail pharmaceutical market. It has eight manufacturing plants located throughout the country. With their net income standing robust at a whopping 220 million USD, CIPLA markets as the 42nd largest publicly traded company by India’s market value. What makes it even better is that it is the world's largest drug manufacturer to fight HIV-AIDS. Equity shares of CIPLA are listed in the Bombay stock exchange, India’s National stock exchange, and the Luxembourg Stock Exchange.

SERVICES

Cipla has over 2,000 products in 65 therapeutic categories.

  • It gives prescription medicines for every sort of disease -- arthritis, cancer, depression -- as well as the staple meds for colds, oral hygiene, and skincare. 

  • The firm also makes bulk drugs, agrochemicals, and animal products. 

  • They manufacture antiretroviral drugs for HIV-AIDS.

  • They also deal in anti-depressants, and steroids like Fluticasone propionate, to treat asthma and other such ailments.

  • CIPLA deals in active pharmaceutical ingredients with other manufacturers as well.

  • They also cooperate with other enterprises in consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.

    MERGERS AND ACQUISITIONS

  • In 2018 CIPLA bought US-based pharmaceutical Avenue Therapeutics for as much as 215 million USD.

  • In 2016 CIPLA joined itself with two other US-based pharmaceutical forces named InvaGen Pharmaceuticals and Exelan Pharmaceuticals to expand its reach in the United States.

  • In 2015 Cipla started a joint venture with Cooper Pharma and The Pharmaceutical Institute. It will focus on respiratory and neurology products.

  • 2020 Cipla and Stempeutics collaborate for the launch of Stempeucel, the first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI).

    MILESTONES

  • 1960-CIPLA commercialises the technology to extract diosgenin from Dioscorea tubers for the first time in India.

  • 1968-turnover crosses the 1CR mark.

  • 1972- Changing the patent law to bring affordable pharma in India. 

  • 1991- turnover crosses Rs. 100 crores

  • 2000- launched a range of CFC-free metered dose inhalers and the world’s first CFC-free budesonide inhaler.

  • 2001- In a paradigm-changing move, Cipla offers a triple AntiRetroViral cocktail to Médecins Sans Frontières (MSF) for $350/patient/year to battle HIV/AIDS. A drug helping patients with HIV costing less than a dollar per day.

  • 2017-Launch of Cipla SAGA (Sub-Saharan Africa and Global Access)

  • 2020- Favipiravir is an oral antiviral drug for clinical recovery in COVID -19 patients with mild to moderate symptoms

ACHIEVEMENTS
  • In 1980, Cipla won the Chemexcil Award for Excellence for exports.

  • In 2005 Dr Y.K. Hamied wins the coveted Padma Bhushan Award by the late President of India, Dr A. P. J. Abdul Kalam.

  • Cipla won the Dun & Bradstreet American Express Corporate Awards in 2006.

  • In 2007, Forbes included Cipla in the 200 'Best under a Billion' list of best small Asian companies.

  • In 2012, Cipla received the Thomson Reuters India Innovation Award.

  • In 2014, Economic Times Lifetime Achievement Award.

  • In 2015, Cipla stood third in India's Most Reputed Brands (Pharmaceutical) list.

  • APR 2020-21 Certified great place to work

ABOUT INVEST YADNYA

Invest Yadnya is a company that educates and simplifies the concepts of personal finance for each individual. We have amalgamated technology with financial planning expertise to help an individual meet their financial objectives. We invest time, money, and knowledge to build financial literacy in India.

We offer various products and services including, Personalized Financial Planning, Stock Market Analysis with eBook Subscriptions, Simplest Income Tax Information Bank, Comprehensive Mutual Fund Reviews, and Do-It-Yourself Financial Planning.


Invest Yadnya should be a choice because it offers unbiased and transparent stock analysis reports. Our work is knowledge-based and has specific proprietary methodologies and a stock research framework. We continuously keep updating our data and have the latest information available. 


We help our clients do extensive research on 950+ companies, including fundamental CIPLA stock analysis. You can find the latest CIPLA stock price on Invest Yadnya. We also provide our clients with the Cipla balance sheet. It helps the clients understand the financial position of the company before making any investment decisions. The Cipla stock analysis helps the investors identify the intrinsic worth of the security. Cipla results provide a summary of how the business incurs revenues and expenses. We also offer our clients with the Cipla share price graph.


Detailed Stock Articles on Cipla vs DRL Stock Comparison: Part 1 & Part 2 are provided on our website, which offers an in-depth Cipla stock review. It gives an investor a sense of whether the company is growing, stable or deteriorating. This helps investors make a viable investment decision with a thorough discussion on Cipla annual report & Cipla research report.

Invest Yadnya offers numerous resources for Cipla share analysis. With the available Cipla financial statements, price chart, ratios, etc., get a detailed analysis of the company. With Invest Yadnya’s available resources, get an overview of the company, both from the qualitative and financial perspective. With Cipla financial statement analysis, the investors shall make a viable investment decision depending on your risk profile & other economic factors.

The Cipla analysis gives the clients a better understanding of the company’s EPS, Debt-Equity Ratio etc. It helps clients take the first step in choosing which companies to invest in. 

The ratio analysis of Cipla overall helps allocate the equity in the Portfolio of an investor to add to its favourable returns.

To find the Cipla Performance analysis & Cipla stock chart, subscribe to our Equity Research and Stock Fundamental Analysis Tool, Stock-O-Meter.

Our website has information about 113 other Pharmaceuticals & Drugs companies that give insight into its financials. Companies include Divis Laboratories, Dr Reddy's Laboratories, Sun Pharmaceutical Industries, Biocon, Aurobindo Pharma, Lupin, Torrent Pharmaceuticals, Cadila Healthcare, Abbott India, Glaxosmithkline Pharmaceuticals & many more.


LATEST UPDATE

premium Premium
free Free
Read More

REPORTS


Comment

Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya